Evidence map›Paper›PMID 41449247›Full record

ArticleDiscover oncology2025

Postbiotic-mediated gut microbiome modulation enhances R-CHOP efficacy in high-risk diffuse large B-cell lymphoma: a case report.

Xiujie Liu, Donghai Cheng, Fangyan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiujie LiuNottingham Ningbo China Beacons of Excellence Research and Innovation Institute, The University of Nottingham Ningbo, Ningbo, 315100, China.
Donghai ChengDepartment of Oncology, Southern Theater Command General Hospital, PLA, Guangzhou, 510010, China.
Fangyan WangInstitute of microbiota and host inflammation-related diseases, School of Basic Medical Science, Wenzhou Medical University, Wenzhou, 325035, China. fangyan_wang@wmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report describes an adult with high-risk DLBCL (IPI score 4) treated with R-CHOP combined with JK5G and JK21 postbiotics for gut microbiome modulation. The patient achieved significant tumor regression while maintaining stable hematological parameters. Microbial analysis demonstrated enrichment of beneficial genera (Veillonella, Bacteroides, Roseburia), potentially linked to postbiotic intervention. Notably, the regimen exhibited excellent tolerability without leukopenia or severe toxicities, suggesting postbiotics may enhance chemotherapy efficacy through microbiome-immune interactions while mitigating adverse effects. These findings warrant further investigation into postbiotics as adjuvant therapy for optimizing DLBCL treatment outcomes.

Indexed as

Diffuse large B-cell lymphomaGut microbiomeImmune modulationImmunotherapyPostbioticsR-CHOP chemotherapy

Identifiers

PMID41449247
PMCPMC12847573

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.